| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
GB:GSK
GlaxoSmithKline
|
Jun 09, 2026 | BUY |
Hold
-2.9% avg upside
25 analysts
|
$2630.00
36.59% Upside
|
· |
|
GB:AZN
AstraZeneca
|
Jun 05, 2026 | BUY |
Strong Buy
+12.2% avg upside
26 analysts
|
$18600.00
40.54% Upside
|
· |
|
GB:0QW0
arGEN X
|
May 12, 2026 | BUY |
Strong Buy
-24.9% avg upside
24 analysts
|
$877.00
13.92% Upside
|
· |
|
GB:0QIU
Novo Nordisk
|
May 06, 2026 | SELL |
Hold
+43.2% avg upside
28 analysts
|
$175.00
40.31% Downside
|
· |
|
CH:NOVN
Novartis AG
|
Apr 29, 2026 | HOLD |
Buy
-9.8% avg upside
30 analysts
|
$125.00
5.58% Upside
|
· |
|
FR:SAN
Sanofi
|
Apr 28, 2026 | BUY |
Strong Buy
+32.9% avg upside
30 analysts
|
$107.00
44.41% Upside
|
· |
|
CH:ROP
Roche Holding AG
|
Apr 27, 2026 | BUY |
Buy
+3.3% avg upside
23 analysts
|
$395.00
23.48% Upside
|
· |
|
NVS
Novartis
|
Mar 19, 2026 | HOLD |
Hold
-7.5% avg upside
24 analysts
|
— | +1.8% |
|
DE:MRK
Merck KGaA
|
Mar 18, 2026 | HOLD |
Buy
+2.2% avg upside
32 analysts
|
$112.00
15.69% Downside
|
· |
|
GB:0MGB
Genmab A/S
|
Feb 23, 2026 | SELL |
Buy
+31.5% avg upside
22 analysts
|
$1400.00
14.76% Downside
|
· |
|
GMAB
Genmab
|
Sep 08, 2025 | SELL |
Buy
+38.3% avg upside
26 analysts
|
— | +3.6% |
|
PFE
Pfizer
|
Aug 17, 2025 | HOLD |
Buy
+34.2% avg upside
45 analysts
|
— | +5.8% |
|
FR:EAPI
Euroapi SA
|
Mar 31, 2025 | HOLD |
Buy
+536.4% avg upside
5 analysts
|
$2.90
131.55% Upside
|
· |
|
ES:GRF
Grifols
|
Dec 10, 2024 | BUY |
Buy
+64.4% avg upside
12 analysts
|
$21.50
136.29% Upside
|
· |
|
MRK
Merck & Company
|
Mar 11, 2024 | SELL |
Strong Buy
+10.7% avg upside
43 analysts
|
$104.00
8.74% Downside
|
-0.2% |
|
BMY
Bristol-Myers Squibb
|
Mar 11, 2024 | HOLD |
Buy
+9.1% avg upside
42 analysts
|
$51.00
5.61% Downside
|
+21.7% |
|
CH:LONN
Lonza Group Ltd
|
Dec 13, 2023 | BUY |
Strong Buy
+26.0% avg upside
19 analysts
|
$544.00
9.03% Upside
|
· |
|
DE:FME
Fresenius Medical Care AG & Co. KGaA
|
Nov 17, 2023 | BUY |
Buy
+27.6% avg upside
21 analysts
|
$71.00
74.46% Upside
|
· |
|
DE:FRE
Fresenius SE & Co. KGaA
|
Nov 17, 2023 | BUY |
Strong Buy
+29.4% avg upside
19 analysts
|
$70.00
76.69% Upside
|
· |
|
RHHBY
Roche Holding
|
Feb 27, 2023 | BUY |
Buy
+0.3% avg upside
14 analysts
|
— | +21.9% |
|
ABBV
AbbVie
|
Nov 08, 2022 | HOLD |
Buy
+2.9% avg upside
43 analysts
|
$140.00
35.37% Downside
|
+44.9% |
|
GSK
GlaxoSmithKline
|
Sep 03, 2019 | BUY |
Hold
-13.9% avg upside
19 analysts
|
— | +8.9% |
|
FSNUY
Fresenius SE & Co
|
Nov 12, 2018 | BUY |
Strong Buy
-11.2% avg upside
6 analysts
|
— | -23.6% |
|
FMS
Fresenius Medical Care
|
Feb 24, 2017 | HOLD |
Buy
+97.2% avg upside
13 analysts
|
— | -1.2% |
|
LLY
Eli Lilly & Co
|
Apr 07, 2016 | HOLD |
Strong Buy
-10.5% avg upside
47 analysts
|
$78.00
92.85% Downside
|
+8.6% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.